Application of quetiapine combined with magnesium valproate in bipolar disorder and depression
Objective To explore the application effect of quetiapine combined with magnesium valproate in bipolar disorder and depression.Methods 106 patients with bipolar disorder and depression admitted to Xuancheng Fourth People's Hospital from June 2021 to April 2023 were divided into the group Ⅰ and the group Ⅱ according to random number table method,with 53 cases in each group.The group Ⅰ received magnesium valproate,while the group Ⅱ received low-dose quetiapine fumarate on the basis of the treatment of the group Ⅰ.Both groups received continuous treatment for 8 weeks.The clinical efficacy of two groups after 8 weeks of treatment was compared.The biochemical indicators levels,scores of Positive and Negative Syndrome Scale(PANSS),Montreal Cognitive Assessment(MoCA)and Bech-Rafaelsen Mania Rating Scale(BRMS),quality of life before treatment and after 8 weeks of treatment,and safety during the research period were compared.Results After 8 weeks of treatment,the total effective rate in the group Ⅱ(92.45％)was higher than that in the group Ⅰ(75.47％).Compared with before treatment,after 8 weeks of treatment,the levels of serum prolactin(PRL),thyroid stimulating hormone(TSH)and bilirubin(BIL),and scores of MoCA and quality of life of two groups increased,and the group Ⅱ was higher than the group Ⅰ(P＜0.05).The level of serum uric acid(UA),scores of BRMS and PANSS in both groups decreased,and the group Ⅱ was lower than the group Ⅰ(P＜0.05).Conclusion The combination of quetiapine and magnesium valproate can stabilize the hormone levels in patients with bipolar disorder and depression,effectively relieve oxidative stress,promote the improvement of quality of life,manic symptoms,and mental state,thereby improving clinical treatment efficacy and cognitive function of patients.And this therapy has good safety.
国家科技期刊平台
NSTL
万方数据
